Camp4 Therapeutics Corp (CAMP)

$3.03 +0.05 (1.68%)
Market Cap 61.09M
Revenue (ttm) 650,000.00
Net Income (ttm) -51.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,967.69%
Debt to Equity Ratio 0.00
Volume 102,200
Avg Vol 980,076
Day's Range N/A - N/A
Shares Out 20.16M
Stochastic %K 59%
Beta N/A
Analysts Strong Sell
Price Target $8.50

Company Profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeuti...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 651 8867
Address:
One Kendall Square, 3rd Floor Building 1400 West, Cambridge, United States
BullseyeStock
BullseyeStock Oct. 3 at 1:29 AM
GIPR is the type of setup market is loving right now. When more folks finds this, expecting big things! Float is very small on it, so will go up fast! Be early bulls, GIPR has the parabolic look! GIPR ✅Partnerships = increase revenues ✅Go private = They are undervalued currently compared to peers and revenues ✅Joint venture = would increase share price tremendously ✅Sale of the company = they would get probably 4x-5x minimum their yearly revenues.. $RVPH $CAMP $QCLS $AREB
0 · Reply
Freeballin02
Freeballin02 Oct. 2 at 12:42 PM
$CAMP added 20k updated price target to $7
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 12:38 PM
Cantor Fitzgerald has updated their rating for Camp4 Therapeutics ( $CAMP ) to Overweight with a price target of 7.
0 · Reply
prismmarketview
prismmarketview Oct. 1 at 8:05 PM
(NASDAQ: $CAMP) Camp4 Therapeutics is moving its lead candidate CMP-SYNGAP-01 into GLP toxicology studies, pushing closer to its first-in-human trials. The company recently revealed translational data showing elevated SYNGAP1 protein in both mice and non-human primates following treatment. https://prismmarketview.com/camp4-therapeutics-advances-lead-syngap1-program-into-glp-toxicology-studies/
0 · Reply
cassidy_mcmln
cassidy_mcmln Sep. 25 at 3:32 PM
$CAMP NXXT strong tape expected as logistics optimization scales Oklahoma onboarding plus national deals scream acceleration watch for breakout candles
0 · Reply
HighReturnStocks
HighReturnStocks Sep. 24 at 3:25 PM
$CAMP
0 · Reply
Rafteriffic
Rafteriffic Sep. 24 at 3:09 PM
$CAMP
0 · Reply
SmashingStocks
SmashingStocks Sep. 23 at 5:04 PM
$CAMP
1 · Reply
SmashingStocks
SmashingStocks Sep. 23 at 5:04 PM
$CAMP grizzly attacks camp Camp down 50 percent This is life
0 · Reply
CasperPuff
CasperPuff Sep. 23 at 1:50 PM
$CAMP come on baby. Come back
0 · Reply
Latest News on CAMP
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

Oct 1, 2025, 8:00 AM EDT - 3 days ago

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Sep 10, 2025, 7:00 AM EDT - 24 days ago

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 14, 2025, 4:05 PM EDT - 7 weeks ago

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

May 16, 2025, 6:00 AM EDT - 5 months ago

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

May 13, 2025, 4:05 PM EDT - 5 months ago

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 5 months ago

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

Apr 10, 2025, 6:56 AM EDT - 6 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

EWTX GNFT

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 4:05 PM EDT - 6 months ago

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Mar 18, 2025, 8:00 AM EDT - 7 months ago

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 13, 2025, 10:39 PM EDT - 7 months ago

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 13, 2025, 2:58 PM EDT - 7 months ago

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

CAMP4 to Participate in Upcoming Investor Conferences

Feb 6, 2025, 8:00 AM EST - 8 months ago

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

Jan 7, 2025, 4:05 PM EST - 9 months ago

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 10 months ago

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

CAMP4 Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 4:05 PM EST - 11 months ago

CAMP4 Reports Third Quarter 2024 Financial Results

CAMP4 Analyst Highlights Rare Disease Platform Potential

Nov 5, 2024, 3:06 PM EST - 11 months ago

CAMP4 Analyst Highlights Rare Disease Platform Potential

CAMP4 Announces Pricing of Initial Public Offering

Oct 10, 2024, 7:07 PM EDT - 1 year ago

CAMP4 Announces Pricing of Initial Public Offering

Camp4 Therapeutics Targets IPO On Early Positive Results

Oct 1, 2024, 4:30 PM EDT - 1 year ago

Camp4 Therapeutics Targets IPO On Early Positive Results

Genetic disease biotech CAMP4 Therapeutics files for a $75 million IPO

Sep 20, 2024, 3:35 PM EDT - 1 year ago

Genetic disease biotech CAMP4 Therapeutics files for a $75 million IPO

Kaiser Permanente-backed biopharma CAMP4 files for US IPO

Sep 20, 2024, 2:23 PM EDT - 1 year ago

Kaiser Permanente-backed biopharma CAMP4 files for US IPO

CAMP4 Therapeutics IPO Registration Document (S-1)

Sep 20, 2024, 1:35 PM EDT - 1 year ago

CAMP4 Therapeutics IPO Registration Document (S-1)

CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

Sep 17, 2024, 8:00 AM EDT - 1 year ago

CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

BullseyeStock
BullseyeStock Oct. 3 at 1:29 AM
GIPR is the type of setup market is loving right now. When more folks finds this, expecting big things! Float is very small on it, so will go up fast! Be early bulls, GIPR has the parabolic look! GIPR ✅Partnerships = increase revenues ✅Go private = They are undervalued currently compared to peers and revenues ✅Joint venture = would increase share price tremendously ✅Sale of the company = they would get probably 4x-5x minimum their yearly revenues.. $RVPH $CAMP $QCLS $AREB
0 · Reply
Freeballin02
Freeballin02 Oct. 2 at 12:42 PM
$CAMP added 20k updated price target to $7
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 12:38 PM
Cantor Fitzgerald has updated their rating for Camp4 Therapeutics ( $CAMP ) to Overweight with a price target of 7.
0 · Reply
prismmarketview
prismmarketview Oct. 1 at 8:05 PM
(NASDAQ: $CAMP) Camp4 Therapeutics is moving its lead candidate CMP-SYNGAP-01 into GLP toxicology studies, pushing closer to its first-in-human trials. The company recently revealed translational data showing elevated SYNGAP1 protein in both mice and non-human primates following treatment. https://prismmarketview.com/camp4-therapeutics-advances-lead-syngap1-program-into-glp-toxicology-studies/
0 · Reply
cassidy_mcmln
cassidy_mcmln Sep. 25 at 3:32 PM
$CAMP NXXT strong tape expected as logistics optimization scales Oklahoma onboarding plus national deals scream acceleration watch for breakout candles
0 · Reply
HighReturnStocks
HighReturnStocks Sep. 24 at 3:25 PM
$CAMP
0 · Reply
Rafteriffic
Rafteriffic Sep. 24 at 3:09 PM
$CAMP
0 · Reply
SmashingStocks
SmashingStocks Sep. 23 at 5:04 PM
$CAMP
1 · Reply
SmashingStocks
SmashingStocks Sep. 23 at 5:04 PM
$CAMP grizzly attacks camp Camp down 50 percent This is life
0 · Reply
CasperPuff
CasperPuff Sep. 23 at 1:50 PM
$CAMP come on baby. Come back
0 · Reply
CasperPuff
CasperPuff Sep. 22 at 6:20 PM
$CAMP wow!!!
1 · Reply
Rafteriffic
Rafteriffic Sep. 22 at 4:57 PM
$CAMP 🐂
0 · Reply
Rafteriffic
Rafteriffic Sep. 21 at 10:51 PM
$CAMP I still feel good about this one.
0 · Reply
AtlasFrontier
AtlasFrontier Sep. 20 at 11:11 PM
Ticker BOXL getting a lot of buzz, Can this be the next parabolic runner for next week. I would not be surprised if BOXL has one of those big squeeze rally of 400-500% BOXL fits the theme of what market is sending right now. Low float gems with News. this 1.8M floater has that potential!! Good watches... $BKKT $FORD $CAMP $LXEH
0 · Reply
SmashingStocks
SmashingStocks Sep. 19 at 8:22 PM
$CAMP solid 8% drop today What’s the bottom here?
3 · Reply
YungnredE
YungnredE Sep. 19 at 7:24 PM
$CAMP This one will not rise again until a reverse split. Today was the icing on the cake
2 · Reply
MJMTEXASTRADES
MJMTEXASTRADES Sep. 19 at 6:55 PM
$CAMP My post on X sold sold sold
1 · Reply
CasperPuff
CasperPuff Sep. 19 at 6:07 PM
$CAMP and now I buy more
0 · Reply
MJMTEXASTRADES
MJMTEXASTRADES Sep. 18 at 2:31 PM
$CAMP one thing is for sure the algo is walking this down slowly. witch it is fine for me, it gives me enough time to average down
0 · Reply
MJMTEXASTRADES
MJMTEXASTRADES Sep. 18 at 2:06 PM
$CAMP this is my post on X
0 · Reply
Rafteriffic
Rafteriffic Sep. 17 at 9:31 PM
$CAMP
1 · Reply
GMExAPE
GMExAPE Sep. 17 at 9:23 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $NCTY $HTCO $RXCEL $CDLX $CAMP watching now
0 · Reply